Fingerprint
Dive into the research topics of 'A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically